$TOVX
Theriva Biologics, Inc. Stock $tovx

$tovx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000141057823000428 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.200M	$2.420M	$2.670M
YoY Change	51.2%	-2.65%	104.91%
% of Gross Profit
Research & Development	$2.977M	$3.070M	$2.570M
YoY Change	14.63%	10.47%	30.32%
% of Gross Profit
Depreciation & Amortization	$32.00K	$30.00K	$20.00K
YoY Change	77.78%	130.77%	11.11%
% of Gross Profit
Operating Expenses	$5.178M	$7.330M	$5.014M
YoY Change	21.78%	39.22%	53.1%
Operating Profit	-$5.178M		-$5.014M
YoY Change	21.78%		53.1%
Interest Expense	$370.0K	$310.0K	$160.0K
YoY Change	-1861.9%	15400.0%	7900.0%
% of Operating Profit
Other Income/Expense, Net	$370.0K		$161.0K
YoY Change	-1861.9%		7950.0%
Pretax Income	-$4.808M	-$7.020M	-$4.825M
YoY Change	12.52%	33.38%	47.42%
Income Tax	-$330.0K	-$1.430M	-$335.0K
% Of Pretax Income
Net Earnings	-$4.478M	-$5.590M	-$4.853M
YoY Change	4.8%	6.21%	48.27%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.30		-$0.33
Diluted Earnings Per Share	-$0.30	-$0.35	-$0.33
COMMON SHARES
Basic Shares Outstanding	15.12M	15.84M	15.84M
Diluted Shares Outstanding	15.12M		15.84M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.08M	$41.79M	$50.49M
YoY Change	-36.36%	-37.93%	-30.01%
Cash & Equivalents	$36.08M	$41.80M	$50.49M
Short-Term Investments
Other Short-Term Assets	$3.990M	$3.500M	$2.030M
YoY Change	249.39%	128.31%	42.76%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$4.000K	$87.00K	$214.0K
Total Short-Term Assets	$40.30M	$45.52M	$52.73M
YoY Change	-32.33%	-33.89%	-28.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$324.0K	$345.0K	$262.0K
YoY Change	7.28%	241.58%	127.83%
Goodwill	$5.617M	$5.525M	$4.254M
YoY Change	-3.31%
Intangibles	$19.47M	$19.15M	$20.09M
YoY Change	-10.97%
Long-Term Investments
YoY Change
Other Assets	$120.0K	$120.0K	$110.0K
YoY Change	-4.76%	421.74%	378.26%
Total Long-Term Assets	$27.59M	$26.34M	$25.96M
YoY Change	-6.31%	1647.91%	1560.1%
TOTAL ASSETS
Total Short-Term Assets	$40.30M	$45.52M	$52.73M
Total Long-Term Assets	$27.59M	$26.34M	$25.96M
Total Assets	$67.89M	$71.86M	$78.70M
YoY Change	-23.72%	2.13%	4.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$480.0K	$915.0K	$770.0K
YoY Change	-64.55%	74.62%	-38.65%
Accrued Expenses	$2.076M	$1.496M	$1.411M
YoY Change	35.24%	-22.41%	39.84%
Deferred Revenue
YoY Change
Short-Term Debt	$66.00K	$57.00K	$52.00K
YoY Change	-2.94%
Long-Term Debt Due	$70.00K	$60.00K	$50.00K
YoY Change	2.94%
Total Short-Term Liabilities	$8.619M	$7.060M	$13.19M
YoY Change	-21.47%	98.65%	317.47%
LONG-TERM LIABILITIES
Long-Term Debt	$160.0K	$220.0K	$200.0K
YoY Change	-30.13%
Other Long-Term Liabilities	$7.210M	$8.400M	$3.660M
YoY Change	19.39%	498.72%	161.24%
Total Long-Term Liabilities	$7.370M	$8.620M	$3.860M
YoY Change	17.58%	514.4%	175.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.619M	$7.060M	$13.19M
Total Long-Term Liabilities	$7.370M	$8.620M	$3.860M
Total Liabilities	$17.30M	$17.30M	$20.55M
YoY Change	-17.51%	248.94%	350.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$295.4M	-$291.0M	-$285.4M
YoY Change	7.22%	7.26%	7.28%
Common Stock	$343.9M	$343.8M	$343.6M
YoY Change	0.14%	2.1%	1.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$288.0K	$288.0K
YoY Change
Treasury Stock Shares	$720.2K	$720.0K
Shareholders Equity	$50.59M	$54.56M	$56.39M
YoY Change
Total Liabilities & Shareholders Equity	$67.89M	$71.86M	$78.70M
YoY Change	-23.72%	2.13%	4.76%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$4.478M	-$5.590M	-$4.853M
YoY Change	4.8%	6.21%	48.27%
Depreciation, Depletion And Amortization	$32.00K	$30.00K	$20.00K
YoY Change	77.78%	130.77%	11.11%
Cash From Operating Activities	-$5.610M	-$5.370M	-$4.450M
YoY Change	14.44%	11.64%	106.4%
INVESTING ACTIVITIES
Capital Expenditures	$8.000K	$90.00K	$20.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$8.000K	-$90.00K	-$20.00K
YoY Change	-99.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$55.00K
YoY Change	-96.0%
Cash From Financing Activities	-55.00K	-3.290M	2.740M
YoY Change	-96.0%
NET CHANGE
Cash From Operating Activities	-5.610M	-5.370M	-4.450M
Cash From Investing Activities	-8.000K	-90.00K	-20.00K
Cash From Financing Activities	-55.00K	-3.290M	2.740M
Net Change In Cash	-5.708M	-8.750M	-1.730M
YoY Change	-45.79%	81.91%	-19.76%
FREE CASH FLOW
Cash From Operating Activities	-$5.610M	-$5.370M	-$4.450M
Capital Expenditures	$8.000K	$90.00K	$20.00K
Free Cash Flow	-$5.618M	-$5.460M	-$4.470M
YoY Change	14.61%	13.51%	107.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000894158
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15844061
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14837832
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15844061
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15176927
CY2018Q4	syn	Over Allotment Option Period OverAllotmentOptionPeriod	P45D
CY2022Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-12584
CY2022	dei	Entity Registrant Name EntityRegistrantName	THERIVA BIOLOGICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3808303
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	9605 Medical Center Drive, Ste. 270
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2022	dei	Entity Address Country EntityAddressCountry	MD
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2022	dei	City Area Code CityAreaCode	301
CY2022	dei	Local Phone Number LocalPhoneNumber	417-4364
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	TOVX
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	32700000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15124061
CY2022	dei	Auditor Firm AuditorFirmId	243
CY2022	dei	Auditor Name AuditorName	BDO USA, LLP
CY2022	dei	Auditor Location AuditorLocation	Potomac, Maryland
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41786000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67325000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3734000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1533000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	45520000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	68858000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	345000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	101000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	99000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1199000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1383000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	19150000
CY2022Q4	us-gaap	Goodwill Goodwill	5525000
CY2022Q4	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	23000
CY2021Q4	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	23000
CY2022Q4	us-gaap	Assets Assets	71861000
CY2021Q4	us-gaap	Assets Assets	70365000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	915000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	524000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1496000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1928000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1403000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	978000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2973000
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	57000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	216000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	124000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7060000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3554000
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7211000
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	221000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1618000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1187000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1403000
CY2022Q4	us-gaap	Liabilities Liabilities	17297000
CY2021Q4	us-gaap	Liabilities Liabilities	4957000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15844294
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15124061
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13204487
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13204254
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	13000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	343750000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	336679000
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	720000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	288000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-679000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-290969000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-271284000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	51830000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	65408000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71861000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70365000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9858000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6474000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11723000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7800000
CY2022	us-gaap	Operating Expenses OperatingExpenses	21581000
CY2021	us-gaap	Operating Expenses OperatingExpenses	14274000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-21581000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-14274000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-41000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	512000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	471000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21110000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14268000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1425000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Profit Loss ProfitLoss	-19685000
CY2021	us-gaap	Profit Loss ProfitLoss	-14268000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19685000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14267000
CY2022	syn	Effect Of Warrant Exercise Price Adjustment EffectOfWarrantExercisePriceAdjustment	340000
CY2021	syn	Effect Of Warrant Exercise Price Adjustment EffectOfWarrantExercisePriceAdjustment	0
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20025000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23189000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.90
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.90
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15327328
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15327328
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12187504
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12187504
CY2022	us-gaap	Profit Loss ProfitLoss	-19685000
CY2021	us-gaap	Profit Loss ProfitLoss	-14268000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-679000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-20364000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-14268000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20364000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14267000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-7540000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	416000
CY2021	syn	Stock Issued During Period At Market Offering Value StockIssuedDuringPeriodAtMarketOfferingValue	65960000
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24000
CY2021	syn	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	8042000
CY2021	syn	Conversion Of Series Preferred Stock To Common Stock ConversionOfSeriesPreferredStockToCommonStock	12822000
CY2021	us-gaap	Profit Loss ProfitLoss	-14268000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	65408000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	65408000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	475000
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	6599000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	679000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	288000
CY2022	us-gaap	Profit Loss ProfitLoss	-19685000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	51830000
CY2022	us-gaap	Profit Loss ProfitLoss	-19685000
CY2021	us-gaap	Profit Loss ProfitLoss	-14268000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	475000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	416000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1425000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2091000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
CY2022	syn	Increase Decrease Right Of Use Assets IncreaseDecreaseRightOfUseAssets	183000
CY2021	syn	Increase Decrease Right Of Use Assets IncreaseDecreaseRightOfUseAssets	166000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	85000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	87000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	363000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-174000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-385000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-363000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-267000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1004000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	333000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	110000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-124000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-216000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19082000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12890000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	116000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000
CY2022	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	3863000
CY2021	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0
CY2022	syn	Repayment Of Long Term Loans From Vendors RepaymentOfLongTermLoansFromVendors	417000
CY2021	syn	Repayment Of Long Term Loans From Vendors RepaymentOfLongTermLoansFromVendors	0
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4396000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1376000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	3000000
CY2022	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	288000
CY2021	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	65960000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8042000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1930000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	74002000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-32000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25408000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	61098000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67325000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6227000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41885000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67325000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41786000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67325000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	99000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41885000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67325000
CY2022	syn	Fair Value Of Contingent Consideration In Business Combination FairValueOfContingentConsiderationInBusinessCombination	10093000
CY2021	syn	Fair Value Of Contingent Consideration In Business Combination FairValueOfContingentConsiderationInBusinessCombination	0
CY2022	syn	Fair Value Of Equity Issued As Consideration In Business Combination FairValueOfEquityIssuedAsConsiderationInBusinessCombination	6599000
CY2021	syn	Fair Value Of Equity Issued As Consideration In Business Combination FairValueOfEquityIssuedAsConsiderationInBusinessCombination	0
CY2022	syn	Adjustment Of Pre Close Vcn Financing AdjustmentOfPreCloseVcnFinancing	417000
CY2021	syn	Adjustment Of Pre Close Vcn Financing AdjustmentOfPreCloseVcnFinancing	0
CY2022	syn	Goodwill Measurement Period Adjustment GoodwillMeasurementPeriodAdjustment	-1061000
CY2021	syn	Goodwill Measurement Period Adjustment GoodwillMeasurementPeriodAdjustment	0
CY2022	syn	In Process Research And Development Measurement Period Adjustment InProcessResearchAndDevelopmentMeasurementPeriodAdjustment	810000
CY2021	syn	In Process Research And Development Measurement Period Adjustment InProcessResearchAndDevelopmentMeasurementPeriodAdjustment	0
CY2022	syn	Deferred Tax Liability Measurement Period Adjustment DeferredTaxLiabilityMeasurementPeriodAdjustment	202000
CY2021	syn	Deferred Tax Liability Measurement Period Adjustment DeferredTaxLiabilityMeasurementPeriodAdjustment	0
CY2022	syn	Warrant Exercise Price Adjustment WarrantExercisePriceAdjustment	340000
CY2021	syn	Warrant Exercise Price Adjustment WarrantExercisePriceAdjustment	0
CY2022	syn	Preferred Stock Price Adjustment PreferredStockPriceAdjustment	0
CY2021	syn	Preferred Stock Price Adjustment PreferredStockPriceAdjustment	7402000
CY2022	syn	Return Of Syn Biomics Stock ReturnOfSynBiomicsStock	0
CY2021	syn	Return Of Syn Biomics Stock ReturnOfSynBiomicsStock	2774000
CY2022	syn	Deemed Dividends With Beneficial Conversion Feature DeemedDividendsWithBeneficialConversionFeature	0
CY2021	syn	Deemed Dividends With Beneficial Conversion Feature DeemedDividendsWithBeneficialConversionFeature	1496000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1270000
CY2022	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	0
CY2021	us-gaap	Dividends Preferred Stock Paidinkind DividendsPreferredStockPaidinkind	24000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	10
CY2022Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	158437840
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15844061
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41800000
CY2021	syn	Proceeds From Issuance Atm Offering Net Of Issuance Costs ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts	66000000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8000000.0
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, research and development costs, business combinations, contingent consideration, fair value of long-lived assets, warrants, preferred stock and stock options granted for services or compensation, respectively, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</p>
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	85000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	87000
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022	syn	Long Lived Assets For Assets Property Equipment And Right Of Use Assets. LongLivedAssetsForAssetsPropertyEquipmentAndRightOfUseAssets.	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Long-lived assets include property, equipment and right-of-use assets. Management reviews the Company’s long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset’s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and the carrying value of the asset. No impairment charges were recorded during the year ended December 31, 2022 and 2021.</p>
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	800000
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	700000
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	2300000
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	500000
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11100000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2100000
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Restatement of Previously Issued Unaudited Interim Consolidated Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the preparation of its consolidated financial statements for the twelve months ended December 31, 2022, the Company determined that its previously issued unaudited interim consolidated financial statements for the periods ended June 30, and September 30, 2022 contained errors in the application of U.S. generally accepted accounting principles as summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Application of FASB ASC 740 Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the preparation of its annual tax provision for the year ended December 31, 2022, the Company determined that a deferred tax asset related to VCN’s indefinite-lived net operating loss generated during the second and third quarters of 2022 should have been established. Further, because of an existing deferred tax liability associated with an indefinite-lived intangible asset is considered a source of income for the deferred tax asset, the deferred tax asset was determined to be more likely than not recoverable. Since the deferred tax asset was determined to be more likely than not recoverable it would have resulted in an income tax benefit during the interim periods thereby reducing the Company’s consolidated net loss and loss per share for the three- and six-months periods ended June 30, 2022 and the three- and nine-month periods ended September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restatement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with Staff Accounting Bulletin ("SAB") No. 99, Materiality, the Company evaluated these misstatements and, based on an analysis of quantitative and qualitative factors, determined that the impact of these misstatements was material to its reporting periods ended June 30, 2022 and September 30, 2022. Accordingly, the Company has restated its unaudited interim consolidated financial statements for the interim reporting periods as of June 30, 2022 and for the three- and six-months then ended and as of September 30, 2022 and for the three- and nine-months then ended, and has included those restated financial statements within this annual report. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Immaterial Adjustments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we are restating prior periods, we are also reflecting other immaterial adjustments related to the valuation of the contingent consideration liabilities and the in process research and development asset, which has a corresponding effect on the associated deferred tax liability and recorded goodwill. It was determined that incorrect clinical trial success rates were used in the determination of the fair value of the contingent consideration liabilities and the in process research and development asset for the interim reporting periods as of June 30, 2022 and for the three and six-months then ended and as of September 30, 2022 and for the three and nine-months then ended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See<i style="font-style:italic;"> Note 14</i> <i style="font-style:italic;">-</i> <i style="font-style:italic;">Restatement of Previously Reported Unaudited Interim Consolidated Financial Statements (Unaudited)</i> for restatement of the Company's previously reported unaudited interim consolidated financial statements that were impacted by these misstatements.</p>
CY2021Q4	syn	Prepaid Clinical Research Organizations Expense Current PrepaidClinicalResearchOrganizationsExpenseCurrent	458000
CY2022Q4	syn	Prepaid Manufacturing Expense PrepaidManufacturingExpense	418000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	637000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	803000
CY2022Q4	syn	Amount Receivable From Prior Owner AmountReceivableFromPriorOwner	144000
CY2022Q4	syn	Prepaid Consulting Subscriptions And Other Expenses PrepaidConsultingSubscriptionsAndOtherExpenses	155000
CY2022	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Financial Liabilities BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialLiabilities	277000
CY2022	syn	Measurement Period Adjustment MeasurementPeriodAdjustment	810000
CY2022	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	607000
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	176000
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	6757000
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	1061000
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	171000
CY2022Q4	us-gaap	Goodwill Goodwill	5525000
CY2022Q4	syn	Prepaid Clinical Research Organizations Expense Current PrepaidClinicalResearchOrganizationsExpenseCurrent	2293000
CY2021Q4	syn	Prepaid Consulting Subscriptions And Other Expenses PrepaidConsultingSubscriptionsAndOtherExpenses	272000
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	87000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3734000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1533000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1210000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	932000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	865000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	831000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	345000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	101000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	85000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	87000
CY2022Q4	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	807000
CY2021Q4	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	696000
CY2022Q4	syn	Accrued Vendor Payments AccruedVendorPayments	492000
CY2021Q4	syn	Accrued Vendor Payments AccruedVendorPayments	1028000
CY2022Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	197000
CY2021Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	204000
CY2022Q4	syn	Accrued Liabilities Current. AccruedLiabilitiesCurrent.	1496000
CY2021Q4	syn	Accrued Liabilities Current. AccruedLiabilitiesCurrent.	1928000
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1216000
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	886000
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	100000
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	92000
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	87000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1403000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	978000
CY2021	syn	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice	0.33
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.92
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0112
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y3M18D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y3M18D
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	997000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2018Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	18600000
CY2018Q4	syn	Warrant Term WarrantTerm	P5Y
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1000
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	13.80
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020	syn	Warrant Exercise Price Adjustment WarrantExercisePriceAdjustment	900000
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8000000.0
CY2021	syn	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	0
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Convertible Conversion Price Decrease PreferredStockConvertibleConversionPriceDecrease	1.22
CY2022	syn	Effect Of Warrant Exercise Price Adjustment EffectOfWarrantExercisePriceAdjustment	340000
CY2022	syn	Estimated Fair Value Of Inducement Consideration EstimatedFairValueOfInducementConsideration	7400000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1800072
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.24
CY2021	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	1165575
CY2021	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	1.24
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	634497
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.24
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	71
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	182
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	634426
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.22
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.00
CY2022Q3	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	3000000.0
CY2021Q3	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	1.22
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2459016
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000
CY2022Q3	syn	Votes Relating To Preferred Stock VotesRelatingToPreferredStock	1549295
CY2018Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	18600000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	252000
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	13.80
CY2018Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.22
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	13.80
CY2020Q4	us-gaap	Preferred Stock Convertible Conversion Price Decrease PreferredStockConvertibleConversionPriceDecrease	6.90
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.90
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	syn	Effect Of Warrant Exercise Price Adjustment EffectOfWarrantExercisePriceAdjustment	340000
CY2021	syn	Preferred Stock Shares Converted PreferredStockSharesConverted	398
CY2021Q1	us-gaap	Preferred Stock Convertible Conversion Price Decrease PreferredStockConvertibleConversionPriceDecrease	15.0
CY2021Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	899677
CY2021Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	899677
CY2022	syn	Estimated Fair Value Of Inducement Consideration EstimatedFairValueOfInducementConsideration	7400000
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	0
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	99000
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	57000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	221000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	57000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	61000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	63000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	52000
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	32000
CY2022Q4	syn	Long Term Debt Maturity Year Six LongTermDebtMaturityYearSix	13000
CY2022Q4	syn	Long Term Debt. LongTermDebt.	278000
CY2022Q4	us-gaap	Payments To Employees PaymentsToEmployees	614250
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	569000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	280000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	327000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	337000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	347000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	357000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	368000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1736000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	333000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1403000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	216000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1187000
CY2017Q4	us-gaap	Payments For Fees PaymentsForFees	4500000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1400000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0647
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0819
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0646
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0818
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4033000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3045000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-677000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-931000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	41000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	32000
CY2022	syn	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Amount EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRateAmount	-1000
CY2021	syn	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Amount EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRateAmount	932000
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-212000
CY2022	syn	Effective Income Tax Rate Reconciliation Forfeited Nqso Trueup EffectiveIncomeTaxRateReconciliationForfeitedNqsoTrueup	-422000
CY2022	syn	Effective Income Tax Rate Reconciliation Transaction Costs EffectiveIncomeTaxRateReconciliationTransactionCosts	-41000
CY2022	syn	Effective Income Tax Rate Reconciliation Fair Market Value Adjustment Contingent Consideration EffectiveIncomeTaxRateReconciliationFairMarketValueAdjustmentContingentConsideration	-439000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	54000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-2901000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-3012000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1425000
CY2022Q4	syn	Deferred Tax Assets Operating Loss Carryforwards Domestic And State And Local DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal	22235000
CY2021Q4	syn	Deferred Tax Assets Operating Loss Carryforwards Domestic And State And Local DeferredTaxAssetsOperatingLossCarryforwardsDomesticAndStateAndLocal	16884000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	29000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	27000
CY2022Q4	syn	Deferred Tax Assets Stocks Issued For Services DeferredTaxAssetsStocksIssuedForServices	1053000
CY2021Q4	syn	Deferred Tax Assets Stocks Issued For Services DeferredTaxAssetsStocksIssuedForServices	1504000
CY2022Q4	syn	Deferred Tax Assets Stock Issued For Acquisition Of Program DeferredTaxAssetsStockIssuedForAcquisitionOfProgram	1456000
CY2021Q4	syn	Deferred Tax Assets Stock Issued For Acquisition Of Program DeferredTaxAssetsStockIssuedForAcquisitionOfProgram	1462000
CY2022Q4	syn	Deferred Tax Assets Stock Issued Forlicense Agreement DeferredTaxAssetsStockIssuedForlicenseAgreement	1362000
CY2021Q4	syn	Deferred Tax Assets Stock Issued Forlicense Agreement DeferredTaxAssetsStockIssuedForlicenseAgreement	1363000
CY2022Q4	syn	Deferred Tax Assets Stock Issued For Milestone Payment DeferredTaxAssetsStockIssuedForMilestonePayment	0
CY2021Q4	syn	Deferred Tax Assets Stock Issued For Milestone Payment DeferredTaxAssetsStockIssuedForMilestonePayment	236000
CY2022Q4	syn	Deferred Tax Assets Tax Deferred Expense Amortizable License Fee DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee	4000
CY2021Q4	syn	Deferred Tax Assets Tax Deferred Expense Amortizable License Fee DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee	4000
CY2022Q4	syn	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	-1592000
CY2021Q4	syn	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	0
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27731000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21480000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24562000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21480000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3169000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q4	syn	Deferred Tax Asset In Process Research And Development DeferredTaxAssetInProcessResearchAndDevelopment	4787000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4787000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1618000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	65800000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52266000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2622000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	54888000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	285000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	96000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1292000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17840000
CY2022Q2	us-gaap	Goodwill Goodwill	6218000
CY2022Q2	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	23000
CY2022Q2	us-gaap	Assets Assets	80642000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1003000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1987000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	788000
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8457000
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent	56000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	128000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12419000
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2195000
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	216000
CY2022Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2293000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1298000
CY2022Q2	us-gaap	Liabilities Liabilities	18421000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15844294
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15844061
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13204487
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13204254
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	16000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	343500000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1261000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-280034000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	62221000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80642000
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50490000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2241000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	52731000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	262000
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	90000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1246000
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17537000
CY2022Q3	us-gaap	Goodwill Goodwill	5223000
CY2022Q3	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	23000
CY2022Q3	us-gaap	Assets Assets	77112000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	770000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1411000
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1319000
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8614000
CY2022Q3	us-gaap	Loans Payable Current LoansPayableCurrent	52000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	157000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12323000
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2237000
CY2022Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	202000
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1984000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1244000
CY2022Q3	us-gaap	Liabilities Liabilities	17990000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15844294
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15844061
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13204487
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13204254
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	16000
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	343621000
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2725000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-284524000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	56388000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	77112000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1541000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3485000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	5026000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5026000
CY2022Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9000
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	26000
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5009000
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-532000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-4477000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4477000
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4477000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15844061
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4477000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1497000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5974000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5974000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3196000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6082000
	us-gaap	Operating Expenses OperatingExpenses	9278000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9278000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-31000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	27000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9282000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-532000
	us-gaap	Profit Loss ProfitLoss	-8750000
	us-gaap	Net Income Loss NetIncomeLoss	-8750000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8750000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14837832
	us-gaap	Net Income Loss NetIncomeLoss	-8750000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1317000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-10067000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10067000
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2416000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2570000
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4986000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4986000
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-9000
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	170000
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	161000
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4825000
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-335000
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-4490000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4490000
CY2022Q3	syn	Effect Of Warrant Exercise Price Adjustment EffectOfWarrantExercisePriceAdjustment	340000
CY2022Q3	syn	Net Loss Attributable To Common Stockholder NetLossAttributableToCommonStockholder	-4830000
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15844061
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4490000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1527000
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-6017000
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6017000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5612000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8652000
	us-gaap	Operating Expenses OperatingExpenses	14264000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14264000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-40000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	197000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	157000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14107000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-867000
	us-gaap	Profit Loss ProfitLoss	-13240000
	us-gaap	Net Income Loss NetIncomeLoss	-13240000
	syn	Effect Of Warrant Exercise Price Adjustment EffectOfWarrantExercisePriceAdjustment	340000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13580000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15176927
	us-gaap	Net Income Loss NetIncomeLoss	-13240000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2844000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-16084000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16084000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	65408000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	112000
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	6599000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	-181000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4273000
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68027000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	113000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	1442000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4477000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	62221000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-121000
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax	1464000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4490000
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	56388000
	us-gaap	Profit Loss ProfitLoss	-8750000
	us-gaap	Share Based Compensation ShareBasedCompensation	225000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-532000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-442000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-518000
	syn	Increase Decrease Right Of Use Assets IncreaseDecreaseRightOfUseAssets	90000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-295000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	265000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-272000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-101000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9258000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	3863000
	syn	Repayment Of Long Term Loans From Vendors RepaymentOfLongTermLoansFromVendors	417000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4294000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1376000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1376000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-35000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14963000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67325000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52362000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52266000
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	96000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52362000
	syn	Fair Value Of Contingent Consideration In Business Combination FairValueOfContingentConsiderationInBusinessCombination	12158000
	syn	Fair Value Of Equity Issued As Consideration In Business Combination FairValueOfEquityIssuedAsConsiderationInBusinessCombination	6599000
	syn	Adjustment Of Pre Close Vcn Financing AdjustmentOfPreCloseVcnFinancing	417000
	syn	Goodwill Measurement Period Adjustment GoodwillMeasurementPeriodAdjustment	277000
	us-gaap	Profit Loss ProfitLoss	-13240000
	us-gaap	Share Based Compensation ShareBasedCompensation	346000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-867000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-244000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	60000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-780000
	syn	Increase Decrease Right Of Use Assets IncreaseDecreaseRightOfUseAssets	137000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-504000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-326000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	271000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-127000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13714000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	3863000
	syn	Repayment Of Long Term Loans From Vendors RepaymentOfLongTermLoansFromVendors	417000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4305000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1358000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-84000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16661000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67325000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50580000
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50490000
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	90000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50580000
	syn	Fair Value Of Contingent Consideration In Business Combination FairValueOfContingentConsiderationInBusinessCombination	12158000
	syn	Fair Value Of Equity Issued As Consideration In Business Combination FairValueOfEquityIssuedAsConsiderationInBusinessCombination	6599000
	syn	Adjustment Of Pre Close Vcn Financing AdjustmentOfPreCloseVcnFinancing	417000
	syn	Goodwill Measurement Period Adjustment GoodwillMeasurementPeriodAdjustment	-884000
	syn	In Process Research And Development Measurement Period Adjustment InProcessResearchAndDevelopmentMeasurementPeriodAdjustment	810000
	syn	Deferred Tax Liability Measurement Period Adjustment DeferredTaxLiabilityMeasurementPeriodAdjustment	202000
	syn	Warrant Exercise Price Adjustment WarrantExercisePriceAdjustment	340000

Files In Submission

Name	View Source	Status
0001410578-23-000428-index-headers.html	Edgar Link	pending
0001410578-23-000428-index.html	Edgar Link	pending
0001410578-23-000428.txt	Edgar Link	pending
0001410578-23-000428-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tmb-20221231.xsd	Edgar Link	pending
tmb-20221231x10k.htm	Edgar Link	pending
tmb-20221231x10k001.jpg	Edgar Link	pending
tmb-20221231x10k002.jpg	Edgar Link	pending
tmb-20221231xex21d1.htm	Edgar Link	pending
tmb-20221231xex23d1.htm	Edgar Link	pending
tmb-20221231xex31d1.htm	Edgar Link	pending
tmb-20221231xex32d1.htm	Edgar Link	pending
tmb-20221231xex4d4.htm	Edgar Link	pending
tmb-20221231_cal.xml	Edgar Link	unprocessable
tmb-20221231_def.xml	Edgar Link	unprocessable
tmb-20221231_lab.xml	Edgar Link	unprocessable
tmb-20221231_pre.xml	Edgar Link	unprocessable
tmb-20221231x10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TOVX
Theriva Biologics, Inc. Stock $tovx

2023 Q1 Form 10-K Financial Statement

#000141057823000428 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX Theriva Biologics, Inc. Stock $tovx

2023 Q1 Form 10-K Financial Statement

#000141057823000428 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX
Theriva Biologics, Inc. Stock $tovx